Cogent Biosciences Stock Up 346% as Fund Builds $29 Million Stake After November Phase 3 Breakthrough
The Motley Fool
by newsfeedback@fool.com (Jonathan Ponciano)February 17, 2026
Cogent Biosciences develops precision therapies for genetically defined diseases, with a pipeline targeting rare oncological conditions.
Verticals
financeinvesting
Originally published on The Motley Fool on 2/17/2026